Research progress on the mechanism and clinical data of IDO inhibitor in reversing the resistance of malignancies to PD-1 antibody by regulating MDSCs / 中国肿瘤临床

ABSTRACT

PD-1 antibody immunotherapy has been used as a first-line treatment against various malignancies,but resistance to this treatment limits its efficacy.For instance,myeloid derived suppressor cells,myeloid derived suppressor cells induce resistance to PD-1 antibody in a tumor microenvironment.A few combination regimens of an IDO inhibitor plus PD-1 antibody are currently subjected to ongoing clinical trials in the US,and preliminary results have shown that this inhibitor can reverse the resistance of malignancies to PD-1 antibody.This study reviewed the research progress on the resistance mechanism of malignancies to PD-1 antibody and revealed that IDO inhibitor regulates MDSCs to reverse the resistance to PD-1 antibody.This study also described the clinical efficacy of this in-hibitor plus PD-1 antibody.